➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Johnson and Johnson
McKinsey
Moodys
McKesson

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

Claims for Patent: RE46209

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE46209
Title:Glue composition for lung volume reduction
Abstract: The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema.
Inventor(s): Gong; Glen (San Francisco, CA), Dieck; Ronald (Palo Alto, CA)
Assignee: PneumRx, Inc. (Mountain View, CA)
Application Number:14/699,818
Patent Claims:1. A method of reducing lung volume in a lung of a subject in need thereof, comprising: administering an effective amount of a glue composition to a localized region of damaged lung tissue of the subject, wherein the glue composition comprises a polyvinylalcohol polymer and a cross-linker, such that the polymer and cross-linker form a hydrogel in the lung, thereby reducing lung volume in the lung of the subject.

2. The method of claim 1, wherein said lung tissue comprises epithelial lining fluid.

3. The method of claim 1, wherein said administering delivers said glue composition to a deep lung region.

4. The method of claim 1, wherein said method is performed with prior identification of said damaged lung tissue.

5. The method of claim 1, wherein said glue composition further comprises a sclerosing agent that damages epithelial cells within lung tissue.

6. The method of claim 5, wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase.

7. The method of claim 1, wherein said glue composition is less than 10 microns.

8. The method of claim 1, wherein said glue composition is less than 5 microns.

9. The method of claim 1, wherein said glue composition is less than 1 micron.

10. The method of claim 1, wherein said administering is carded out via inhalation.

11. The method of claim 10, wherein said inhalation is carried out via the mouth.

12. The method of claim 1, wherein said administering is carried out via trans-thoracic administration.

13. The method of claim 1, wherein said administering is carried out by placing a bronchoscope in a bronchi of a deep lung region.

14. The method of claim 13, further comprising placing a catheter through said bronchoscope to reach a subsegmental bronchi.

15. The method of claim 14, wherein said catheter comprises an expandable balloon-like structure.

16. The method of claim 1, wherein said subject is suffering from a pulmonary condition.

17. The method of claim 16, wherein said pulmonary condition is emphysema or chronic obstructive pulmonary disease.

18. A method of reducing lung volume in a lung of a subject in need thereof comprising: providing a glue composition comprising a cross-linkable moiety and a polyvinylalcohol; administering said glue composition to a localized region of the lung tissue of the subject; and cross-linking said cross-linkable moiety and said polyvinylalcohol to form a hydrogel, thereby reducing lung volume.

19. The method of claim 18, wherein said glue composition further comprises a sclerosing agent that damages epithelial cells within lung tissue.

20. The method of claim 19, wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase.

.Iadd.21. The method of claim 1, wherein the cross-linker is glutaraldehyde..Iaddend.

.Iadd.22. The method of claim 1, wherein the glue composition further comprises a rate modifier..Iaddend.

.Iadd.23. The method of claim 1, wherein the glue composition further comprises an anti-secretory agent..Iaddend.

.Iadd.24. The method of claim 23, wherein the anti-secretory agent is selected from the group consisting of anticholinergic moieties, atronie, and atropinic moieties..Iaddend.

.Iadd.25. A method of sealing air spaces in a localized region of lung tissue in a subject, comprising: administering an effective amount of a glue composition to the air spaces in the localized region of lung tissue of the subject, wherein the glue composition comprises a polyvinylalcohol polymer and a cross-linker, such that the polymer and cross-linker form a hydrogel in the lung, thereby sealing the air spaces in the localized region of lung tissue of the subject..Iaddend.

.Iadd.26. The method of claim 25, wherein the localized region is a site of damaged lung tissue..Iaddend.

.Iadd.27. The method of claim 25, wherein the air spaces are within alveoli..Iaddend.

.Iadd.28. The method of claim 26, wherein the air spaces are within enlarged alveoli distal to a terminal bronchiole..Iaddend.

.Iadd.29. The method of claim 26, wherein the air spaces were enlarged air spaces or over-inflated air spaces prior to said administering of the glue composition..Iaddend.

.Iadd.30. The method of claim 26, wherein the air spaces remain in a collapsed or deflated state after said administering of the glue composition..Iaddend.

.Iadd.31. The method of claim 26, wherein said lung tissue comprises epithelial lining fluid..Iaddend.

.Iadd.32. The method of claim 26, wherein said method is performed with prior identification of said damaged lung tissue..Iaddend.

.Iadd.33. The method of claim 25, wherein said administering delivers said glue composition to a deep lung region..Iaddend.

.Iadd.34. The method of claim 25, wherein said cross-linker comprises glutaraldehyde..Iaddend.

.Iadd.35. The method of claim 25, wherein said glue composition further comprises a sclerosing agent that damages epithelial cells within lung tissue..Iaddend.

.Iadd.36. The method of claim 25, wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase..Iaddend.

.Iadd.37. The method of claim 25, wherein said glue composition is less than 10 microns..Iaddend.

.Iadd.38. The method of claim 25, wherein said glue composition is less than 5 microns..Iaddend.

.Iadd.39. The method of claim 25, wherein said glue composition is less than 1 micron..Iaddend.

.Iadd.40. The method of claim 25, wherein said administering is carried out via inhalation..Iaddend.

.Iadd.41. The method of claim 40, wherein said inhalation is carried out via the mouth..Iaddend.

.Iadd.42. The method of claim 25, wherein said administering is carried out via trans-thoracic administration..Iaddend.

.Iadd.43. The method of claim 25, wherein said administering is carried out by placing a bronchoscope in a bronchi of a deep lung region..Iaddend.

.Iadd.44. The method of claim 43, further comprising placing a catheter through said bronchoscope to reach a subsegmental bronchi..Iaddend.

.Iadd.45. The method of claim 44, wherein said catheter comprises an expandable balloon-like structure..Iaddend.

.Iadd.46. The method of claim 25, wherein said subject is suffering from a pulmonary condition..Iaddend.

.Iadd.47. The method of claim 46, wherein said pulmonary condition is emphysema or chronic obstructive pulmonary disease..Iaddend.

.Iadd.48. A method of cross-linking damaged lung tissue of a subject, comprising: administering an effective amount of a glue composition to a localized region of damaged lung tissue of the subject, wherein the glue composition comprises a polyvinylalcohol polymer and a cross-linker, thereby cross-linking the damaged lung tissue of the subject..Iaddend.

.Iadd.49. The method of claim 48, wherein the damaged lung tissue is within an alveolus..Iaddend.

.Iadd.50. The method of claim 48, wherein the damaged lung tissue is within an enlarged alveolus distal to a terminal bronchiole..Iaddend.

.Iadd.51. A method for delivering a glue composition to a lung of a patient, the system comprising: advancing a delivery catheter through a bronchoscope in an airway of the lung of the patient to a localized treatment site of damaged lung tissue; and injecting a glue composition through the delivery catheter to the localized treatment site, wherein the glue composition comprises a polyvinylalcohol polymer and a cross-linker, such that the polymer and cross-linker form a hydrogel in the lung upon administration, thereby delivering the glue composition to the lung of the patient..Iaddend.

.Iadd.52. The method of claim 51, wherein said catheter comprises an expandable balloon-like structure..Iaddend.

.Iadd.53. The method of claim 51, wherein the cross-linker is glutaraldehyde..Iaddend.

.Iadd.54. The method of claim 51, wherein said glue composition further comprises a sclerosing agent that damages epithelial cells within lung tissue..Iaddend.

.Iadd.55. The method of claim 54, wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase..Iaddend.

.Iadd.56. The method of claim 51, wherein said glue composition is less than 10 microns..Iaddend.

.Iadd.57. The method of claim 51, wherein said glue composition is less than 5 microns..Iaddend.

.Iadd.58. The method of claim 51, wherein said glue composition is less than 1 micron..Iaddend.

.Iadd.59. The method of claim 51, wherein said patient is suffering from a pulmonary condition..Iaddend.

.Iadd.60. The method of claim 59, wherein said pulmonary condition is emphysema or chronic obstructive pulmonary disease..Iaddend.

Details for Patent RE46209

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 001 1978-01-16   Start Trial PneumRx, Inc. (Mountain View, CA) 2024-06-16 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 002 1978-01-16   Start Trial PneumRx, Inc. (Mountain View, CA) 2024-06-16 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16   Start Trial PneumRx, Inc. (Mountain View, CA) 2024-06-16 DISCN search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Dow
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.